Taiwan-based premier international contract development and manufacturing organization (CDMO) Bora Pharmaceuticals recently announced the establishment of Bora Biologics Co., Ltd., a CDMO platform for biologics. Besides Bora, investors into the new entity include Taishin Healthcare Limited Partnership and Tanvex BioPharma founder Dr. Allen Chao. Bora also announced that they will initially invest $50 million USD and up to $100 million USD in the acquisition of Eden Biologics’ CDMO assets in Taiwan as part of its 5-year growth plan. With Bora’s strengths as a CDMO for small molecules and biological macromolecules, the company has established a leadership position in Taiwan with its comprehensive CDMO customer services and competitive market share.
In line with its strategy of building comprehensive CDMO capabilities, Bora expands into biologic macromolecules and cell and gene therapy markets
Bora indicated that the strategic acquisition of Eden Biologics CDMO assets, located in Hsinchu Biomedical Science Park, Taiwan, will help Bora Group rapidly build a presence in the biological macromolecules and cell and gene therapy markets, and position the organization to expand its service offering to their clients supporting new and innovative drug development.
Bora chairman Bobby Sheng explained that the acquisition of Eden Biologic’s CDMO assets is an important milestone as Bora continues to expand its presence in the CDMO market. Bora has always been committed to the creation of a global CDMO with comprehensive capabilities. The strategic cooperation with Taishin Healthcare Limited Partnership and Dr. Allen Chao is in line with the firm’s long-term investment strategy for growth.
Expanding production capacity with international standards-based manufacturing processes and technologies
With the acquisition of the facility, Bora will have biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, along with the establishment of quality control and inspection specifications, as well as cell bank generation.
“The addition of the CDMO facilities state of the art equipment and the expertise of the highly qualified team gives Bora Biologics the ability to develop and continue with our clients as they progress to commercialization.” Bora Vice President Simon Chen said.
Mr. Chen further explained that the facility has four 500L bioreactors, all of which have been certified by the EU Qualified Person (QP) and the Taiwan Food and Drug Administration, Ministry of Health and Welfare. The facility has proven its comprehensive CDMO capabilities by having completed several collaborative projects with many international partners.